
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Almac Group announced the acquisition of 100% shares of BioClin Laboratories. BioClin will bring fourth its expert analytical services and analysis to increase Almac’s capacity and compliment its existing business strategic expansion which will help them to serve clients globally.
Read the full release






